Chronic Bronchitis News and Research

RSS

Drug can be delivered safely to people with COPD in both "mist" and "dry powder" inhalers, say experts

An international study led by a Johns Hopkins pulmonary expert finds that the drug tiotropium (marketed as the Spiriva brand), can be delivered safely and effectively to people with chronic obstructive pulmonary disease (COPD) in both "mist" and traditional "dry powder" inhalers.

10 Sep 2013

COPDF launches pocket consultant guide iPhone app for effective diagnosis, therapy of COPD

The COPD Foundation (COPDF) announces today the launch of its COPD Pocket Consultant Guide (PCG) iPhone app, a practical tool designed to facilitate easier, more effective diagnosis and therapy for Chronic Obstructive Pulmonary Disease (COPD) during daily clinical care.

7 Sep 2013

Okana acquires North American product rights for FACTIVE tablets from Merus Labs International

Okana Ventures Inc. is pleased to announce the acquisition of the North American product rights for FACTIVE® (Gemifloxacin Mesylate) tablets from Merus Labs International for approximately US$3.4 million.

31 Aug 2013

Call for global COPD education shakeup

Researchers behind a global survey of chronic obstructive pulmonary disease patients say that more must be done to educate patients about the disease and what to do during exacerbations.

30 Aug 2013

Investigators link acute viral infections to development of COPD

Investigators at Washington University School of Medicine in St. Louis have described another link in the chain of events that connect acute viral infections to the development of chronic obstructive pulmonary disease (COPD).

16 Aug 2013

Lung Volume Reduction Coil may play key role in treatment of emphysema, study finds

A small, easily implantable device called the Lung Volume Reduction Coil may play a key role in the treatment of two types of emphysema, according to a study conducted in Europe. Results of the study indicate the beneficial effects of the device persist more than a year after initial treatment.

21 May 2013

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference in Philadelphia, PA, May 17 – 22.

20 May 2013

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

As part of the company's commitment to chronic obstructive pulmonary disease patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals and patients that the transition to COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of COPD is nearly complete.

18 May 2013

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.

13 May 2013

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

GlaxoSmithKline plc and Theravance, Inc. today announced that the Pulmonary-Allergy Drugs Advisory Committee to the US Food and Drug Administration voted that the efficacy and safety data provide substantial evidence to support approval of BREO ELLIPTA as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (9 for, 4 against) and also for the reduction of COPD exacerbations in patients with a history of exacerbations (9 for, 4 against).

18 Apr 2013

ACOEM provides tools, resources to help employers identify and respond to impact of COPD

Awareness campaign for the workplace provides tools and information on preventing and managing chronic obstructive pulmonary disease - the third leading cause of death in the U.S.

12 Apr 2013

Relighting cigarettes related to economic factors, researchers find

In what is believed to be a first of its kind study, a research member at The Cancer Institute of New Jersey and colleagues have found that an accelerating trend of smokers relighting cigarettes is related to economic factors, and the practice has implications for tobacco dependence treatment and policy.

19 Mar 2013

Chronic obstructive pulmonary disease (COPD) inflammatory subtypes: an interview with Dr Vanessa McDonald, University of Newcastle, Australia

COPD is defined as a preventable and treatable disease associated with significant extrapulmonary consequences that may contribute to severity. The pulmonary component of COPD is characterised by airflow limitation that is not fully reversible. The airflow limitation is usually progressive with an abnormal inflammatory response of the lungs to noxious particles (GOLD Strategy Document). Airflow obstruction in COPD is not highly variable and largely irreversible.

8 Mar 2013

Chronic Bronchitis News and Research

Drug can be delivered safely to people with COPD in both "mist" and "dry powder" inhalers, say experts

COPDF launches pocket consultant guide iPhone app for effective diagnosis, therapy of COPD

Okana acquires North American product rights for FACTIVE tablets from Merus Labs International

Call for global COPD education shakeup

Investigators link acute viral infections to development of COPD

Lung Volume Reduction Coil may play key role in treatment of emphysema, study finds

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

ACOEM provides tools, resources to help employers identify and respond to impact of COPD

Relighting cigarettes related to economic factors, researchers find

Chronic obstructive pulmonary disease (COPD) inflammatory subtypes: an interview with Dr Vanessa McDonald, University of Newcastle, Australia

FDA approves Lupin Pharmaceuticals' SUPRAX for Oral Suspension

Bronchiectasis finding reveals COPD patients at mortality risk

Older adults with COPD more frequently use benzodiazepines

COPD underdiagnosed in Chinese lung cancer patients

Almirall, Forest Laboratories' Tudorza Pressair now available in the U.S. pharmacies

BRFSS survey offers state-level rates of COPD prevalence

MRC funds largest ever study of genetics relating to lung disease

Snapping at new biotech breakthroughs with Gator Pro

Realizing the Importance of Medical Electronic Devices

Everything about SpatialOMx

Latest News

Omics eBook